Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Palupiprant
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Adlai Nortye Doses First Patient in Phase II Trial of Palupiprant for Rectal Cancer
Details :
Product Name : AN0025
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 22, 2024
Lead Product(s) : Palupiprant
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Buparlisib,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : AN2025
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 17, 2023
Lead Product(s) : Buparlisib,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Buparlisib,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Cantor Fitzgerald
Deal Size : $106.1 million
Deal Type : Public Offering
Adlai Nortye Ltd. Announces Pricing of Initial Public Offering
Details :
Product Name : AN2025
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 29, 2023
Lead Product(s) : Buparlisib,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Cantor Fitzgerald
Deal Size : $106.1 million
Deal Type : Public Offering
Lead Product(s) : Buparlisib,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Nucleai
Deal Size : Undisclosed
Deal Type : Partnership
Details :
Product Name : AN2025
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 31, 2023
Lead Product(s) : Buparlisib,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Nucleai
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Buparlisib,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Cantor Fitzgerald
Deal Size : $57.5 million
Deal Type : Public Offering
Adlai Nortye Ltd. Announces Closing of Initial Public Offering
Details :
Product Name : AN2025
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 10, 2023
Lead Product(s) : Buparlisib,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Cantor Fitzgerald
Deal Size : $57.5 million
Deal Type : Public Offering
Lead Product(s) : Pelareorep,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Oncolytics Biotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
October 14, 2021
Lead Product(s) : Pelareorep,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Oncolytics Biotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Palupiprant,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : AN0025
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 24, 2020
Lead Product(s) : Palupiprant,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable